Statens Serum Institut
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Statens Serum Institut
Promising Results In GSK Study Could Break Years Of TB Vaccine Deadlock
GlaxoSmithKline has published results from its latest Phase IIb trial of its investigational tuberculosis vaccine that show a subunit vaccine can reduce pulmonary TB, possibly leading the way for the first new vaccine for TB in over 90 years.
- Academic and Research Institutions
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.